AML: Using Available Evidence and Guidelines to Make Sense of a Rapidly Evolving Treatment Paradigm

Get up to date on optimal use of new agents and approaches in the care of your patients with AML with downloadable slides from a live Webinar along with a clinical resource.

Share

Program Content

Activities

2020 AML Resource Guide
2020 AML Treatment Algorithms and Key Phase III Clinical Trials: A Clinician’s Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2020

Expires: December 03, 2021

Activities

ND AML Tx Without Targets
Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2020

Expires: December 03, 2021

ND AML Tx With Targets
Selecting Therapy for AML With Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2020

Expires: December 03, 2021

MRD and Maintenance in AML
New and Novel Advances in AML Therapeutics
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 04, 2020

Expires: December 03, 2021

<i>EP</i>: AML Treatment Paradigm
ExpressPoints: Using Available Evidence and Guidelines for Managing an Evolving AML Treatment Paradigm
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from

Agios Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Pfizer, Inc.